Back

BMC Medicine

155 training papers 2019-06-25 – 2026-03-07

Top medRxiv preprints most likely to be published in this journal, ranked by match strength.

1
Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia
2026-03-04 epidemiology 10.64898/2026.03.02.26347477
#1 (21.8%)
Show abstract

BackgroundTwo RSV immunisations products: a maternal vaccine, Abrysvo, and a long-acting monoclonal antibody, nirsevimab, both designed to prevent RSV illness in infants, have recently become available. Modelling evidence is required to inform how to optimally use these products in immunisation programs to reduce the burden of RSV in young children. MethodsWe extend a dynamic transmission model calibrated to RSV-hospitalisation data of children aged < 5 years in temperate Western Australia (WA)...

2
Eligibility Without Equity: Rethinking Age-Based Adult Vaccine Policies
2026-02-18 public and global health 10.64898/2026.02.17.26346473
#1 (14.3%)
Show abstract

Embedding equity into vaccine eligibility is essential for reducing health inequalities. Yet, adult vaccine eligibility in most European countries is primarily based on fixed age thresholds, prioritising cost-effectiveness. This approach risks excluding the most vulnerable populations living in deprived communities with poorer health and shorter survival into older age. Extending eligibility based on clinical risk partially addresses this gap. Higher rates of underdiagnosis and delayed diagnosis...

3
Optimal seasonal timing of infant immunisation to prevent RSV hospitalisations in Japan: a modelling study
2026-02-17 infectious diseases 10.64898/2026.02.14.26346252
Top 0.1% (11.2%)
Show abstract

The seasonal circulation of respiratory syncytial virus (RSV) in countries such as Japan, together with the transient nature of passive immunity conferred to infants via maternal vaccination or monoclonal antibody administration, may warrant a differential strategy for those born during the RSV inter-seasonal period. Maximal effectiveness may be achieved by deferring immunisation of this cohort from birth until entry into their first RSV season using catch-up administration of monoclonal antibod...

4
Economic burden of cancer and cardiovascular disease mortality among working-age Europeans: A lifecycle modelling study
2026-02-24 health economics 10.64898/2026.02.13.26346233
Top 0.1% (10.7%)
Show abstract

ObjectivesNon-communicable diseases (NCDs) account for almost 90% of deaths in Europe, yet comparative estimates of the productivity costs associated with premature NCD mortality across diseases and countries remain limited. This study estimates and compares productivity losses attributable to cardiovascular disease (CVD) and cancer mortality among working-age populations across Europe. Population-based data were used to estimate productivity costs for CVD and cancer deaths across 30 European co...

5
Cost-effectiveness of High-Dose Influenza Vaccination in the Netherlands: Updated Analysis Incorporating New Evidence
2026-02-18 health economics 10.64898/2026.02.17.26346451
Top 0.2% (9.8%)
Show abstract

BackgroundHigh-dose inactivated influenza vaccination (HD-IIV) demonstrates superior effectiveness versus standard-dose vaccination (SD-IIV) in adults aged [&ge;]60 years. A recent meta-analysis integrated complementary evidence sources of representing over 85 million individuals across 14 influenza seasons. MethodsA previously developed model was updated using life-time horizon and societal perspective. Updated parameters included demographics, costs, hospitalization rates, and relative vaccin...

6
Potential public health and economic impact of the next-generation COVID-19 vaccine mRNA-1283 in the Netherlands
2026-02-19 health economics 10.64898/2026.02.18.26346561
Top 0.3% (8.7%)
Show abstract

COVID-19 remains a substantial public health challenge in the Netherlands. Next-generation COVID-19 vaccine, mRNA-1283, is approved in the European Union, with potential for higher relative vaccine efficacy compared with originally-licensed COVID-19 vaccines. Its potential public health and economic impact, in adults [&ge;]60 years and high-risk 18-59 years, was modelled versus no vaccination and originally-licensed mRNA-1273 and BNT162b2, adapting a published static Markov model with 1-year tim...

7
The age paradox in post-infectious sequelae: physiological reserve outweighs chronological age in Long COVID susceptibility
2026-02-26 public and global health 10.64898/2026.02.24.26346989
Top 0.3% (8.7%)
Show abstract

BackgroundOlder age is widely considered a risk factor for post-acute sequelae of SARS-CoV-2 infection (PASC), typically attributed to immunosenescence and inflammaging. However, whether this association reflects intrinsic biological ageing or accumulated comorbidity burden remains unclear, with implications for clinical risk stratification. MethodsWe conducted a retrospective cohort study using the Precision PASC Research Cohort (P2RC) from Mass General Brigham, comprising 133,792 COVID-19 pat...

8
The Hidden Burden of Mortality Across the Spectrum of ICD-10 Conditions in Australia: A Multiple Cause of Death Analysis
2026-02-09 epidemiology 10.64898/2026.02.07.26345820
Top 0.3% (8.6%)
Show abstract

BackgroundDeath certificates record both an underlying cause and contributing conditions, yet mortality statistics predominantly report only the underlying cause. We quantify this "hidden burden" across all ICD-10 conditions in Australian mortality data using the multiple-to-underlying ratio (MUR): total death certificate mentions divided by underlying cause deaths. MethodsWe analysed Australian Bureau of Statistics Causes of Death 2023 data (N = 187,268 registered deaths) to compute the ratio ...

9
Age-structured dynamics and susceptibility in the face of infection and vaccination
2026-02-11 epidemiology 10.64898/2026.02.10.26345956
Top 0.4% (8.2%)
Show abstract

BackgroundStrikingly low allocation of SARS-CoV-2 vaccine to the African Continent limits its capacity to control transmission. Characterizing the trajectory of vaccination efforts and their impact on the expected burden of SARS-CoV-2 will help planning vaccine delivery strategies, and public health interventions more broadly. As the burden is strongly age-dependent, this requires an understanding of the age-structured dynamics of susceptible individuals, accounting for the combined effects of v...

10
Standardisation of terminology, calculation and reporting for assigning exposure duration to drug utilisation records from healthcare data sources: the CreateDoT framework
2026-02-19 epidemiology 10.64898/2026.02.18.26346576
Top 0.5% (7.5%)
Show abstract

BackgroundIn pharmacoepidemiological studies, days of treatment (DoT) duration associated with individual electronic drug utilization records (DUR) are usually missing. Researcher-defined duration (RDD) calculation approaches, as opposed to data-driven approaches, can be used to estimate DoT based on the specific choices and assumptions made by investigators. These are usually underreported or even undocumented. We aimed to develop a framework for the standardization of terminology, formulas, im...

11
Monitoring influenza-like symptoms in the UK through participatory surveillance: insights from FluSurvey over two winter seasons (2023-24 and 2024-25)
2026-02-15 public and global health 10.64898/2026.02.12.26345150
Top 0.7% (7.3%)
Show abstract

FluSurvey is a participatory surveillance system used to monitor trends in influenza and other respiratory viruses through weekly symptom surveys among the UK population. We aimed to characterise the wider impact of "influenza-like illnesses" (ILI) among FluSurvey participants and assess correlations of ILI with other established influenza surveillance systems. We included data reported by FluSurvey participants over the 2023-24 and 2024-25 winter seasons. Using weekly symptoms surveys, we deri...

12
Disruption and recovery of notifiable infectious diseases after COVID-19 in Australia, 2015-2025
2026-02-17 public and global health 10.64898/2026.02.13.26346301
Top 0.8% (6.8%)
Show abstract

BackgroundCOVID-19 non-pharmaceutical interventions (NPIs) disrupted transmission of many infectious diseases worldwide. While disruption patterns are well-documented, systematic analysis of post-pandemic recovery trajectories across diverse pathogens remains limited. We examined disruption and recovery of 47 nationally notifiable diseases in Australia from 2015 to 2025. MethodsWe analysed NNDSS surveillance data for 47 diseases across six transmission modes, quantifying disruption using observ...

13
Cohort study investigating the natural history and management of sore throat and tonsillitis among adults in UK general practice
2026-02-17 primary care research 10.64898/2026.02.16.26346374
Top 0.8% (6.8%)
Show abstract

BackgroundRecurrent sore throat affects a small minority of adults but can cause substantial morbidity. Evidence to guide tonsillectomy eligibility in adults is limited, and current criteria are extrapolated from paediatric populations. We aimed to describe the epidemiology, management, and prognosis of adult sore throat in UK primary care. MethodsUsing CPRD Aurum (2010-2020 adults with a first coded episode of sore throat or tonsillitis were identified and matched to controls. Episode frequenc...

14
Data Driven Endocrine Metabolic Phenotypes in Young Women With Polycystic Ovary Syndrome and Associations With Cardiometabolic Risk Markers
2026-03-03 endocrinology 10.64898/2026.02.25.26346893
Top 0.9% (6.6%)
Show abstract

ContextPolycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder associated with reproductive dysfunction and long-term cardiometabolic risk. Traditional phenotype classifications based on diagnostic criteria may not fully capture the multidimensional biological variability underlying endocrine and metabolic risk profiles, particularly in young women. ObjectiveTo identify data-driven endocrine-metabolic phenotypes in young women with PCOS and evaluate their association with establi...

15
Early health technology assessment of digital diabetes screening in Switzerland: cost-effectiveness and budget impact analyses
2026-02-11 health economics 10.64898/2026.02.10.26345992
Top 0.9% (6.5%)
Show abstract

ObjectivesDigital biomarkers offer scalable screening for type 2 diabetes, yet adoption is stalled by uncertainty regarding economic viability. This study evaluates the cost-effectiveness and budget impact of digital screening compared to opportunistic screening from a Swiss payer perspective. MethodsA probabilistic Markov cohort model was developed to simulate at-risk Swiss adults (age [&ge;]45, BMI [&ge;]25 kg/m{superscript 2}) over a 40-year horizon. The model incorporates a digital attritio...

16
The impact of patient ethnicity on cancer incidence following platelet count and C-reactive protein tests in English primary care: a cohort study of 5 million patients
2026-03-04 primary care research 10.64898/2026.03.03.26347503
Top 0.9% (6.5%)
Show abstract

BackgroundPlatelet count and C-reactive protein (CRP) are blood tests commonly used in primary care as part of diagnostic work up for symptomatic patients. Abnormal results of these tests can indicate an undetected cancer; however, it is not known whether the association between an abnormal test result and cancer risk varies by patient ethnicity. MethodsThis cohort study used routinely collected primary and secondary health care records in England with linkage to national cancer registry data. ...

17
Genome-Wide Association Study of Creatinine Clearance Identifies New Loci for Kidney Function
2026-03-05 nephrology 10.64898/2026.03.04.26347652
Top 1.0% (6.5%)
Show abstract

IntroductionGenome-wide association studies (GWAS) for kidney function have mainly focused on creatinine-based glomerular filtration rate (eGFRcrea), which is affected by variation in muscle mass. Moreover, the genetic basis of the sexual dimorphism of chronic kidney disease is underexplored. MethodsWe performed a GWA meta-analysis for creatinine clearance (CrCl), a muscle mass-independent kidney function phenotype, in 58,976 individuals of European descent from the Lifelines Cohort Study. Res...

18
A Biopsychosocial Risk Score for Stratifying Disease Vulnerability in Healthy Populations: A Prospective Cohort and Multi-Omics Study in the UK Biobank
2026-02-10 public and global health 10.64898/2026.02.08.26345832
Top 1.0% (6.4%)
Show abstract

Proactive identification of systemic vulnerability for disease(s) before clinical onset in healthy individuals is an ultimate goal of preventive and precision medicine, yet current tools remain largely disease-specific and fail to quantify latent vulnerability, an integrative measure of underlying health status, for early prevention and risk-stratified intervention. To address this, we developed the Risk Score for Disease Vulnerability (RS4DV) based on 85 accessible biopsychosocial measures, whi...

19
Comparison of methods for assessing effects of risk factors on disease progression in Mendelian randomization under index event bias
2026-03-02 epidemiology 10.64898/2026.02.26.26347193
Top 1% (6.4%)
Show abstract

Mendelian randomization has emerged as a transformative approach for inferring causal relationships between risk factors and disease outcomes. However, applying Mendelian randomization to disease progression - a critical step in validating pharmacological targets - is hampered by index event bias. This form of selection bias occurs because analyses of disease progression are necessarily restricted to individuals who have already experienced the disease event. Here, we present a comprehensive eva...

20
Personal-MetaboHealth, an actionable health check in middle age, is improved by an effective lifestyle intervention in those at risk
2026-02-17 public and global health 10.64898/2026.02.15.26346369
Top 1% (6.3%)
Show abstract

The biomarker MetaboHealth represents a novel indicator of overall health in middle age and may potentially be suitable as actionable health check in prevention strategies. MetaboHealth is a blood-based metabolomic composite score that predicts a wide range of age-related conditions and mortality in large European cohorts. Here, we investigated whether MetaboHealth can be personalised and limited to clinically validated metabolomic markers. Next, we assessed whether the updated MetaboHealth scor...